Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 10 of 23
Jun 7, 2026Boehringer Ingelheim’s investigational drug Survodutide has demonstrated encouraging effects on liver fat reduction in obesity patients, though new data suggest its effect on overall weight loss may be less competitive compared to rival treatments. This nuanced outcome influences the drug’s potential role in obesity management strategies.
Jonathan Blake
Jun 6, 2026Pfizer's recent midstage study results of the obesity drug Berobenatide, acquired through its deal with Metsera, offer encouraging evidence supporting monthly dosing. This development could impact obesity treatment paradigms amid growing demand for effective, patient-friendly regimens.
Michael Torres
Jun 6, 2026Zealand Pharma and Roche have presented Phase 2 data on their amylin analog, petrelintide, showing about 9% weight loss. Although this outcome is below expectations relative to competitors, executives emphasized the distinct positioning and therapeutic goal of their obesity treatment candidate at the recent ADA conference.
Michael Torres
Jun 6, 2026As part of its broader workforce reductions and operational restructuring, Merck is continuing to downsize its New Jersey site in Rahway. This development follows earlier cuts and reflects ongoing challenges in the pharmaceutical sector that are prompting companies to rethink their workforce needs and operations.
Daniel Cho
Jun 3, 2026Biotech industry leaders are confronting unprecedented pressure driven by Chinese innovation and advances in artificial intelligence. The perspectives of emerging CEOs reveal how the next generation of industry pioneers aims to tackle these challenges head-on while steering the future of biotechnology.
Sophia Reynolds
Jun 2, 2026In a striking development within the biotech sector, Fulcrum Therapeutics halted development of its lead candidate amid concerns about secondary malignancies linked to similar drugs. The company's decision comes in the wake of regulatory actions against a competitor, underscoring the challenges in balancing therapeutic potential and patient safety.
Sophia Reynolds
Jun 1, 2026In a significant move within the biopharmaceutical sector, Servier is set to expand its neuromuscular disease portfolio by purchasing a promising candidate drug from Edgewise Therapeutics. This acquisition reflects growing investment interests in therapies tackling muscular dystrophy, a debilitating group of genetic disorders.
Dr. Priya Nandakumar
May 31, 2026Prostate cancer remains a leading cause of cancer morbidity in men worldwide. Traditional treatment involves surgery, but post-surgical relapse is common. This study explores an upfront hormone therapy regimen aimed at improving surgical outcomes by lowering the chances of cancer returning. The encouraging results from ASCO 2026 could influence future standards of care.
Sophia Reynolds
May 29, 2026The deal marks a strategic push for Pfizer into the Chinese oncology market and adds a robust pipeline of candidates targeting diverse cancer types. The collaboration could reshape global cancer treatment options as antibody-based therapeutics gain prominence.
Dr. Alex Morgan
May 28, 2026Following the trajectory set by Eli Lilly in obesity medicine, Kailera Therapeutics is developing a suite of weight management drugs including injectable and oral GLP-1 based therapies, and an ambitious triple-agonist candidate known as the 'triple-G' drug. These efforts position the company for a catalyst-rich post-IPO period in a rapidly evolving biopharma landscape.
Michael Torres
May 28, 2026Navigating job offers in a market favoring employers requires a nuanced approach. This article explores expert perspectives on negotiation strategies, frequent mistakes candidates make, and key advice for securing favorable employment terms in the biotech and pharmaceutical industries.
Jonathan Blake
May 27, 2026The pharmaceutical industry continues to reward its top executives handsomely, with the highest paid CEOs in 2025 amassing significant compensation packages. This group includes leaders from major companies such as Eli Lilly and Pfizer, underscoring the industry's robust financial stature and competitive executive landscape.
Sophia ReynoldsMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.